During the analyzed period, the main drivers of the increasing costs in outpatient care were the introduction of innovative drugs, the reimbursement of self-monitoring of blood glucose in insulin-treated persons, HbA1c, and insulin pumps in those with type 1 diabetes [6]. Here, INS is linked to type 1 diabetes mellitus.